A5002331967- Pharmacology and Obesity Treatment
- Plasma Diagnostics and Applications
- Particle accelerators and beam dynamics
- Magnetic confinement fusion research
- Gyrotron and Vacuum Electronics Research
- Dust and Plasma Wave Phenomena
- Cell Adhesion Molecules Research
- Ionosphere and magnetosphere dynamics
- Monoclonal and Polyclonal Antibodies Research
- Laser-Plasma Interactions and Diagnostics
- Hormonal and reproductive studies
- Diabetes Treatment and Management
- Laser-induced spectroscopy and plasma
- Inflammatory Bowel Disease
- Liver Disease Diagnosis and Treatment
- Food Allergy and Anaphylaxis Research
- High-pressure geophysics and materials
- Biochemical Analysis and Sensing Techniques
- Liver Disease and Transplantation
- Particle Accelerators and Free-Electron Lasers
- Atomic and Molecular Physics
- RNA Interference and Gene Delivery
- Phytochemicals and Antioxidant Activities
- Cardiovascular Syncope and Autonomic Disorders
- DNA and Nucleic Acid Chemistry
Connolly Hospital Blanchardstown
2025
Los Alamos National Laboratory
1988-2024
Beaumont Hospital
2023
St. Vincent's University Hospital
2021-2023
South Tipperary General Hospital
2022
University of Edinburgh
2022
University Hospital Waterford
2020
Anthera Pharmaceuticals (United States)
2016-2018
Ibero American University
2016-2017
Arena Pharmaceuticals (United States)
2008-2017
Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight.
Peanut-induced anaphylaxis is an IgE-mediated condition that estimated to affect 1.5 million people and cause 50 100 deaths per year in the United States. TNX-901 a humanized IgG1 monoclonal antibody against IgE recognizes masks epitope CH3 region of responsible for binding high-affinity Fcε receptor on mast cells basophils.
Abstract Context: Lorcaserin is a novel selective agonist of the serotonin 2C receptor. Objective: Our objective was to evaluate effects lorcaserin on body weight, cardiovascular risk factors, and safety in obese overweight patients. Design Setting: This randomized, placebo-controlled, double-blind, parallel arm trial took place at 97 U.S. research centers. Patients: Patients included 4008 patients, aged 18–65 yr, with mass index between 30 45 kg/m2 or 27 29.9 an obesity-related comorbid...
The BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity Overweight Management in Diabetes Mellitus) study evaluated efficacy safety of lorcaserin weight loss patients with type 2 diabetes. Secondary objectives included evaluations glycemic control, lipids, blood pressure, quality life. This 1-year, randomized, placebo-controlled trial enrolled 604 1:1:1 to placebo, 10 mg once daily (QD) or twice (BID). Patients were treated metformin, a sulfonylurea (SFU) both; had glycated...
Background and aims: To evaluate the safety efficacy of intercellular adhesion molecule 1 (ICAM-1) antisense phosphorothioate oligonucleotide alicaforsen (ISIS 2302) in Crohn's disease. Methods: Active (Crohn's disease activity index (CDAI) 200–350), steroid dependent (prednisone 10–40 mg) patients were randomised into three treatment groups: placebo versus ISIS 2302 (2 mg/kg intravenously times a week) for two or four weeks. Patients treated months 3, with withdrawal attempted by week 10....
BackgroundWe wished to determine the safety and anti–human immunodeficiency virus (HIV) type 1 activity of single doses TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent against HIV-1 in vitro, HIV-infected subjects MethodsSequential cohorts 6 HIV-1–infected each received infusions TNX-355. Data included plasma RNA level, CD4+ T cell count, TNX-355 coating cells, serum levels ResultsDose-related reductions loads correlated complete by Peak median decreases were 0.56, 1.33,...
Lorcaserin (APD356) is a potent, selective 5-HT(2C) agonist with ~15-fold and 100-fold selectivity vs. 5-HT(2A) 5-HT(2B) receptors, respectively. This study evaluated the safety efficacy of lorcaserin for weight reduction in obese patients during 12-week period. The randomized, double-blind, placebo-controlled, parallel-arm enrolled 469 men women between ages 18 65 BMI 30-45 kg/m(2). Patients received placebo, 10 mg q.d., 15 or b.i.d. 12 weeks, were counseled to maintain their usual diet...
<h3>Background</h3> Targeted inhibitors of B-cell activating factor (BAFF) have been evaluated in phase III trials over 4000 patients with systemic lupus erythematosus (SLE). Post hoc analyses these studies identify greater treatment effect entering higher disease activity, corticosteroid doses, anti double-stranded DNA (dsDNA) and low complement C3 or C4. <h3>Objectives</h3> To evaluate the efficacy safety blisibimod, a BAFF inhibitor, population SLE enriched for high activity....
Healthy male volunteers received single or multiple intravenous infusions of an intercellular adhesion molecule-1 antisense phosphorothioate oligodeoxynucleotide, ISIS 2302, in a rising-dose (0.06-2.00 mg/kg infused over 2 hr), double-blind, placebo-controlled trial. Brief, dose-related increases activated partial thromboplastin time were seen at the peak plasma concentration (C(max)). Clinically insignificant C3a after higher, repeated doses, but C5a, blood pressure and pulse unaffected. No...
The linear theory of a cold relativistic electron beam propagating parallel to an external magnetic field and through cold, homogeneous plasma is investigated. electromagnetic dispersion relation solved numerically compared with analytical predictions based on the electrostatic approximation. It found that effects are important for determining entire unstable spectrum. However, except strong regime, maximum growth rates corresponding frequencies in agreement those predicted by In regime...
Background— Lorcaserin is a selective 5-HT 2C agonist evaluated for weight management in clinical trials. Echocardiographic monitoring was conducted to test the hypothesis that agonism would avoid valvular heart disease. Methods and Results— change data from 5249 obese overweight patients 3 phase trials were integrated. Treatment duration with 10 mg lorcaserin twice daily or placebo 52 weeks. The proportions of who developed Food Drug Administration–defined valvulopathy (≥ mild aortic ≥...
Background: Lorcaserin, a novel selective 5-HT2C receptor agonist, is approved by the US Food and Drug Administration (FDA) for weight management in combination with lifestyle modification adults obesity overweight ≥ 1 weight-related comorbid condition. The safety effectiveness of lorcaserin adult patients without type 2 diabetes mellitus was established based on phase III clinical trials similar design: Behavioral Modification Lorcaserin Overweight Obesity Management (BLOOM) Second Study...
Lorcaserin is a selective serotonin 2C receptor agonist approved by the Food and Drug Administration for chronic weight management. Preclinical data suggest that it may also be effective in smoking cessation through modulation of dopaminergic reward system. This was 12-week, randomized, double-blind, placebo-controlled trial conducted 30 centers United States. Six hundred three adult smokers with Body Mass Index 18.5–35 kg/m2, averaging at least 10 cigarettes/day no period abstinence >3...
Purpose This phase 2 study was designed to assess the efficacy, safety and tolerability of immediate-release orally administered ralinepag, a selective, non-prostanoid prostacyclin receptor agonist with 24-h terminal half-life, compared placebo in adult patients symptomatic pulmonary arterial hypertension (PAH). Methods 61 PAH who were receiving standard care, including mono or dual PAH-targeted background therapy randomised 2:1 ralinepag (n=40) (n=21). The starting dose 10 μg twice daily....
Objective To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5% weight loss at Week (W) 52 in patients with without type 2 diabetes on lorcaserin or placebo. Methods Post hoc area under the curve receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo modification+lorcaserin. A total 6897 (18–65 years; BMI, 30–45 27–29.9 kg/m2 ≥1 comorbidity) were randomized to placebo 10 mg bid....
Electrical transport properties of dense aluminum are measured in the disordered liquidlike phase using a well-tamped, thermally equilibrated, exploding wire z pinch. Direct measurements electrical conductivity have been made voltage and current measurements. Our span minimum regime, at higher densities than produced previously. We find that some Ziman-like theoretical predictions fair agreement with data one approach is good agreement, contrast to other experiments performed similar regimes...
An investigation of equilibrium, stability, and space-charge- limiting current a solid relativistic beam propagating along finite external magnetic field has been carried out compared with experiments. The concept rigid-rotor equilibrium is only approximately valid when the much less than Alfvèn critical current. Typically, low-voltage beams rotate fastest at edge whereas high-voltage near axis. A limited rigid rotor stability condition indicates, worst, weak instability may be present if...
Insomnia is a condition affecting 10% to 15% of the adult population and characterized by difficulty falling asleep, staying or nonrestorative sleep, accompanied daytime impairment distress. This study evaluates APD125, selective inverse agonist 5-HT(2A) receptor, for treatment chronic insomnia, with particular emphasis on sleep maintenance. In phase 1 studies, APD125 improved maintenance was well tolerated.Adult subjects (n=173) DSM-IV defined primary insomnia were randomized into...
Journal Article Reduction of Acute-Phase Proteins with Tenidap Sodium, a Cytokine-Modulating Anti-Rheumatic Drug Get access L. D. Loose, Loose *Central Research Division, Pfizer Inc.,Groton, CT06340 Correspondence to Central Inc, Eastern Point Road, Groton, CT 06340, USA. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Sipe, Sipe †Boston University School MedicineBoston, MA 02118, USA S. Kirby, Kirby A. R. Kraska, Kraska E. Weiner, Weiner W. Shanahan,...